Abionyx Pharma: €1.9M in Revenue for H1 and Cash Position of €26.9M at End of June
ABIONYX Pharma reported on August 27, 2026 an update on its activity and cash position for the first half of 2026.
The group reported consolidated revenue of €1.9M and cash of €26.9M at the end of June, while its strategic activity, focused on therapies for sepsis and critical care, generated no revenue during the period.
€1.9M in Revenue, Entirely Derived from Iris Pharma Subsidiary
During the first half of 2026, ABIONYX Pharma recorded consolidated revenue of €1.9M, generated entirely by its Iris Pharma subsidiary through its contract research organization (CRO) activities in ophthalmology.
The financial statement shows Iris Pharma revenue of €1.9M in the first half of 2026, compared to €2.1M in the second quarter of 2025. The biotechnology activity, the group's core business, generated no revenue during the quarter.
The company notes that it continued to provide its bioproduct free of charge as part of compassionate use authorization requests (CUA), which explains the absence of revenue from this activity.
€26.9M in Cash Following June Financing
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
As of June 30, 2026, the group's cash and cash equivalents amounted to €26.9M, following the financing transaction announced on June 18 and before the collection of research tax credit and subsidies under the France 2030 plan.
This compares to €3.4M in cash at the end of the period in the second quarter of 2025. The group states that it has financial visibility through the end of 2028.
Iris Pharma Revenue Expected to Remain Stable in 2026
Based on information available at the date of the announcement, the company anticipates that Iris Pharma's revenue for the 2026 fiscal year will remain broadly stable compared to the 2025 fiscal year.
The first half 2026 accounts have not yet been finalized by the board of directors and are subject to limited review by the statutory auditors. The consolidation scope has not changed compared to the previous fiscal year.
SectorSanté · Biotechnologies · Vaccins et laboratoires de recherche›Biotechnologie
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: 1S2026
Key reported figures
Revenue: 1.9M€
Guidance from the release
ABIONYX Pharma affiche un chiffre d'affaires consolidé de 1,9 M€ au S1 2026, généré uniquement par sa filiale IRIS Pharma (CRO en ophtalmologie), tandis que l'activité biotech ne génère aucun revenu, le bioproduit étant fourni gratuitement dans le cadre d'autorisations d'accès compassionnel. La trésorerie s'élève à 26,9 M€ après une opération de financement en juin 2026, avant réception du Crédit Impôt Recherche et des aides France 2030, offrant une visibilité financière jusqu'à fin 2028.
Risks mentioned
Absence de revenu généré par l'activité biotech principale au T2 2026
Bioproduit fourni gratuitement dans le cadre des autorisations d'accès compassionnel, sans revenu associé
Dépendance du chiffre d'affaires consolidé à la seule filiale IRIS Pharma
Opportunities identified
Trésorerie de 26,9 M€ suite à l'opération de financement annoncée le 18 juin 2026
Visibilité financière étendue jusqu'à fin 2028
Chiffre d'affaires d'IRIS Pharma anticipé stable pour l'exercice 2026 par rapport à 2025
Réception attendue de Crédits d'Impôt Recherche et d'aides du plan France 2030 non encore comptabilisées
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
